25.02.2019 | press release, Aktuell

CO.DON AG and GENERIUM JSC sign term sheet to out-license co.don chondrosphere® to Russia

Berlin / Teltow, 25 February 2019 –  CO.DON AG and GENERIUM JSC have agreed to out-license the matrix-associated product co.don chondrosphere® for the Russian market and have signed a corresponding term sheet. GENERIUM JSC is a leading biopharmaceutical company in Russia that focuses on advanced therapy medicinal products (ATMPs) and various recombinant medicines. The planned licensing agreement will cover out-licensing, as well as advisory services, training and knowledge transfer by qualified employees of CO.DON AG.

The licensing agreement is subject to the approval of the Supervisory Board, which is planned for late May 2019.

Ralf Jakobs, CEO of CO.DON AG: “Since we obtained marketing authorisation, our European expansion strategy has been defined by two main pillars: whereas in the European Union we are continuing to expand our market presence with the EU-authorised product in line with our strategy, in other markets, now starting with the Russian market, we consider licensing to be more sensible and economically effective for CO.DON AG. And in GENERIUM JSC we have found an experienced partner that is established in the Russian market. We are looking forward to working with our partner in the period ahead.”

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Tel. +49 (0)30 240352330                        

Fax +49 (0)30 240352309                        

Email: ir@codon.de




Archive press- and

ad hoc-Messages

Earlier vintages may be obtained on request as PDF via e-mail.

» Send inquiry